Inventiva S.A.
IVAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeInventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Valued at $876.4M, IVA is a small-cap name in its sector. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Market Cap
$876.4M
Beta
1.00
P/E (TTM)
—
P/E (Fwd)
-4.99
EPS (TTM)
$-0.62
EPS (Fwd)
$-0.74
ROE
-989.0%
ROA
-42.7%
Cash
$166.1M
Total Debt
$138.8M
Free CF
-$116.1M
52W Change
-46.2%
Annual Financials
Cash vs Debt
Where IVA stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, IVA finished 37.88% below its 150-day moving average ($4.62) and 42.25% below its 200-day moving average ($4.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IVA overbought or oversold?
At the October 15, 2026 close, IVA's RSI(14) was 39.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $166.1M in cash and $138.8M in debt, IVA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$116.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -989.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $12.2M (2022) to $4.5M (2025), a 63% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Inventiva S.A.'s trajectory.